Iovance Biotherapeutics (NASDAQ: IOVA)
Iovance Biotherapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Iovance Biotherapeutics Company Info
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
News & Analysis
Prediction: This Stock Will Beat the Market in 2025
Is Iovance Biotherapeutics Stock a Millionaire Maker?
Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back
2 Innovative Stocks That Could Deliver Outsized Returns
Why Iovance Biotherapeutics Stock Triumphed on Thursday
With a cutting-edge melanoma drug now on the market, the company is positioned for a breakout.
Is Iovance Biotherapeutics Stock a Buy?
The biotech is making important breakthroughs, but is that enough?
3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow
This biotech's growth story is going to start moving faster, and soon.
3 Things You Need to Know if You Buy Iovance Biotherapeutics Today
There's plenty of upside with this stock, but it might take a while to realize.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.